L18 March 20 Dr Choy Immune System Flashcards

1
Q

Describe the fxn of the two types of T cells and what they bind to

A

T cells – recognize specific short peptides (9 – 11 aa for CD8 T cells, ~20 aa for CD4 T cells) in the context of major histocompatibility complex (MHC) molecules.
– Binding is mediated by T cell receptor (TCR)
– CD8 T cells bind peptide in the context of MHC class I
• Kills cells that express the peptide-MHC class I
– CD4 T cells bind peptide in the context of MHC class II
• Secrete cytokines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe fxn of B cell

A

B cells – bind to proteins through B cell receptor (BCR) which is antibody bound to B cell membrane – Activation results in secretion of antibodies – Antibodies bind to proteins in tissues and either kill cells associated with them or activate inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the antigen processing to its display on the cell surface

A
  1. The epitopes recognized by T cell receptors are often buried
  2. The Ag must be 1st broken down into peptide fragments
  3. The epitope peptide bind to a self molecule, MHC molecule
  4. The TCR binds to a complex of MHC molecule and epitope peptide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do peptides wind up on MHC I molecules on the cell surface?

A
  1. Production of proteins in the cytosol
  2. Proteolytic degradation of proteins
  3. Transport of peptides from cytosol to ER
  4. Assembly of peptide-class I complexes in ER
  5. Surface expression of peptide-class I complexes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do peptides wind up on MHC II molecules on the cell surface?

A
  1. Uptake of extracellular proteins into vesicular compartments of APC
  2. Processing of internalized proteins in endosomal/lysosomal vesicles
  3. Biosynthesis and transport of class II MHC molecules to endoscopes
  4. Association of processed peptides with class II MHC molecules in vesicles
  5. Expression of peptide-MHC complexes on cell surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the 5 routes of Ag processing by dendritic cells? Type of pathogen presented? MHC molecule loaded? Type of naive T cell activated?

A
  1. Receptor mediated phagocytosis
    - a) Type of pathogen presented: Extracellular bacteria
    - b) MHC molecule loaded: MHC class II
    - c) Type of naive T cell activated: CD4 T cells
  2. Macro-pinocytosis
    - a) Type of pathogen presented: Extracellular bacteria, soluble antigens, virus particles
    - b) MHC molecule loaded: MHC class II
    - c) Type of naive T cell activated: CD4 T cells
  3. Viral infection
    - a) Type of pathogen presented: Viruses
    - b) MHC molecule loaded: MHC class I
    - c) Type of naive T cell activated: CD8 T cells
  4. Cross-presentation after phagocytic or macropinocytic uptake
    - a) Type of pathogen presented: Viruses
    - b) MHC molecule loaded: MHC class I
    - c) Type of naive T cell activated: CD8 T cell
  5. Transfer from incoming dendritic cell to resident dendritic cell
    - a) Type of pathogen presented: Viruses
    - b) MHC molecule loaded: MHC class I
    - c) Type of naive T cell activated: CD8 T cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the pathway of Ag being taken up by dendritic cell to where it activates T cells

A
  1. Ag uptake by Langerhan cells in skin
  2. Langerhan cells leave skin and enter lymphatic system
  3. Mature dendritic cells enter lymph node from infected tissues and can transfer some Ags to resident dendritic cells
  4. B7 pos dendritic cells stimulate naive T cels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What Three Signals Are Needed to Activate T Cells (delivered by APCs)

A

Signal 1: TCR binding to peptide MHC

The following two are absent normally but induced by inflammation:

Signal 2: Co-stimulatory molecule expression on antigen presenting cell and binding to partner on T cell

Signal 3: Cytokine secretion by APC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What occurs when TCR binding to peptide-MHC (signal 1) only (ie. without signal 2)

A

Results in no activation or inhibition of activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe fxn of CD8 T cells

A
  1. CTL recognizes and binds virus-infected cell
  2. CTL programs target for death, including DNA fragmentation. E.g. release cytotoxic vesicles containing granzymes and perforin.
  3. CTL migrates to new target
  4. Target cell dies by apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Fxn of Treg?

A
  1. Inhibit the activity of effector T cells
    – By doing so prevent immune rxms against Ags
    – Essential for preventing immune rxns to self Ags that cause autoimmunity
    - Maintain tolerance to self antigens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the 2 types of Treg?

A

Natural T regs and induced T regs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What % of CD4 T cells do natural Treg make up? Where do natural Tregs develop?

A

– 5-15% of circulating CD4 T cells
– CD4-positive, FoxP3-positive, CD25-high
– Develop in thymus towards self-antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does peripherally induced Fox3-Pos Tregs (induced T regs) induced?

A

– Induced in the periphery from naïve precursors

– Induced by TGFβ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the mechanisms of suppression of T cells

A
  • Can be antigen-dependent or independent
  • can act in the periphery or in lymph nodes
– Direct	suppression	of	T	cells	
• Soluble	factors	–	Eg.	IL-10,	TGFβ
• Cytotoxicity	–	Granzyme	B	
• Expression	of	inhibitory	surface	proteins	
–	Eg.	CTLA4	
• Generation	of	adenosine	which	is	
immunosuppressive	
• Depletion	of	bioavailable	IL-2	
– Modulation	of	DC	function	
• Cell	contact	dependent	–	recognizes	self	
antigen-MHC	
• Secretion	of	IL-10	and	TGFβ
• Spatial	modulation	of	immune	
responses	 – Inhibition	of	dendritic	cell	migration	to	
lymph	nodes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the self regulation of T cell activation by co inhibitory molecule CTLA4

A

• Induced late after T cell activation

  1. Binds B7s with much higher affinity than CD28
  2. Transduces inhibitory signals to prevent T cell activation
17
Q

How do Abs secreted by plasma B cells aid in immune response

A
  1. Neutralization
    - Abs prevent bacterial adherence
  2. opsonization
    Ab promotes phagocytosis
  3. Complement activation
    - Ab activates complement, which enhances opsonization and lyses some bacteria
18
Q

What are the steps in Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

A
  1. Ab binds Ags on surface of target cells
  2. Fc receptors on NK cells recognize bound Ab
  3. Cross linking of Fc receptors signals NK cell to kill target cell
  4. Target cell dies by apoptosis
19
Q

Describe the Regulation of NK Cell Activation

A
  1. MHC class I on normal cells is recognized by inhibitory receptors that inhibit signals from activating receptors
  2. NK cell doesn’t kill normal cell
  3. Altered or absent MHC class I can’t stimulate a neg signal. The NK cell is triggered by signals from activating receptors
  4. Activated NK cell releases granule contents, inducing apoptosis in target cell
20
Q

What are the 3 immunological components most directly relavent for cancer immunotherapy?

A
  1. T cells
    – CTLs and maybe CD4 T cells that kill tumors
  2. NK cells – kill tumors
  3. Antibodies
    – Target tumors
    – Neutralize tumorigenic processes
    – Target immunoregulatory processes
21
Q

What is the Immune Response Towards Tumors

A
  1. Tumors often infiltrated by T cells, NK cells and macrophages
  2. Abs to some tumor Ags can sometimes be observed
  3. Abundance of lymphocytes in tumors sometimes associated with better prognosis
22
Q

Describe the mouse experiment that demonstrates the immune system protects against cancer

A

Based on the transplantation (via injection) of tumor cells into mice – Must be done into MHC matched strains otherwise allogeneic rejection occurs • When injected, most tumor cells grow and kill the host • If mice are injected with irradiated tumor cells (to prevent cell proliferation) prior to injection with non-irradiated tumors, they are often protected • This protection is not seen in T cell-deficient mice and can be conferred by adoptive transfer of T cells from immunized mice

23
Q

Describe the specificity of anti-tumor response. What are tumor rejection Ags?

A

Tumor rejection antigens: Peptides of cellular proteins bound to MHC molecules on the tumor cell surface • There is specificity of the immune system for cancer type. Irradiated tumor X cells do not provide protection against tumor Y

24
Q

Evidence that Immunosuppression in People Can Lead to Expansion of Cancer

A

One report in which 2 people got kidney transplants from the same donor – Donor had a previous, successfully treated, malignant melanoma • Likely had undetectable melanoma cells in kidney at time of transplant • Both recipients developed melanoma after transplantation – Immunosuppression prevented the control of the melanoma by the host immune system

25
What is immune surveillance? What are the 3 phases?
Immune surveillance: ability of immune system to detect tumors and destroy them 1. Elimination phase: Immune system recognizes and destroys tumor 2. Equilibrium phase: Tumor cells that escape elimination phase undergo mutations that aid in survival and r selected for. Balance between tumor cell mutations n immune targeting so net tumor growth is 0. Process known as cancer immunoediting. 3. Escape phase: Tumor cells that have accumulated enough beneficial mutations elude immune system and grow unimpeded
26
Effector Mechanisms of ImmuneMediated Tumor Elimination
T cells and NK cells needed – RAG and STAT1 deficient mice (no T, B, NK cells) spontaneously develop gut epithelial and breast tumors • Perforin-deficient mice have increased susceptibility to induction of lymphomas • IFNγ and TNF also important in tumor immunity
27
Evidence for tumor immunoediting?
1. Identical tumor cells injected into normal and immunodeficient mice 2. Tumor cells retransplanted into normal mice 3. Tumors passaged in normal mice grow when transferred into second normal mice. Tumors passed in immunodeficient mice rejected when transferred into normal mice.
28
What are tumor antigens and two types?
Tumor Ag: Peptides of tumor cell proteins that are presented to T cells by MHC molecules or protein epitopes that are recognized by antibodies. Types of tumor antigens – Tumor-specific antigens: Antigens expression by tumor cells but not normal cells – Tumor-associated antigens: Tumor antigens that are also expressed on some normal cells
29
Slide 37
NA
30
What are the 5 mechanisms by which tumors avoid immune recognition?
1. Low immunogenicity 2. Tumor treated as self Ag 3. Antigenic modulation 4. Tumor-induced immune suppression 5. Tumor-induced privileged site
31
Goal and rationale of immunotherapy?
Goal: To harness potential of IS system to specifically target n eliminate tumors; Rationale: Immune responses towards tumors r observed in some individuals n mouse models. This indicates that induction of immune responses towards tumors is possible n might be able to eliminate tumors
32
Considerations of immunotherapy
1. Specificity and/or nature of tumor Ags that r targeted 2. Normal tolerance mechanisms against tumor Ag (which is derived from self proteins) 3. Tolerogenic properties of tumor 4. Off-target effects of immunotherapy
33
3 approaches of immunotherapy:
Antibodies – To directly target and destroy tumors – To indirectly target tumor by inhibiting natural tolerogenic processes that prevent endogenous immune response towards tumor • Adoptive T cell therapy – Endogenous tumor-reactive T cells – T cells transduced with a synthetically engineered TCR that targets tumor antigen – T cells modified to express chimeric antigen receptor • Immunization – With tumor antigens – With DCs loaded with tumor antigens
34
Inhibition of Tolerance Mechanisms by Antibodies: Checkpoint Blockade
Inhibition of Tolerance Mechanisms by Antibodies: Checkpoint Blockade; Goal: To interfere with normal inhibitory signals that negatively regulate lymphocyte activation • Eg. CTLA-4 inhibits T cell activation – Blocking CTLA-4 with anti-CTLA-4 increases anti-tumor immune responses and is therapeutically effective towards many types of cancer • Challenge: CTLA4 is needed to prevent autoimmunity • PD-L1 is another “checkpoint” molecule that is targeted for therapeutic benefit